Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 16/20 | 0.71 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109545 | 0.97 | TLR8 (0.75) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109542 | 0.97 | TLR8 (0.75) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109614 | 0.89 | TLR8 (0.71) | TLR8TLR7NLRP3 | |
| SCHEMBL18109611 | 0.89 | TLR8 (0.71) | TLR8TLR7NLRP3 | |
| SCHEMBL18923203 | 0.87 | TLR8 (0.61) | TLR8TLR7NLRP3 | |
| SCHEMBL18125192 | 0.87 | TLR8 (0.61) | TLR8TLR7NLRP3 | |
| SCHEMBL18109286 | 0.87 | TLR8 (0.74) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109289 | 0.87 | TLR8 (0.74) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL19940969 | 0.87 | TLR8 (0.60) | TLR8TLR7NLRP3 | |
| SCHEMBL19940722 | 0.87 | TLR8 (0.60) | TLR8TLR7NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186579-B2 | Therapeutic heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | TLR8 3360/4885TLR7 2795/4885KCNH2 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.